{"analyses":[{"ciLowerLimit":"0.571","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.450","groupDescription":"Teff-high WT Population","groupIds":["OG001","OG002"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6899","paramType":"Hazard Ratio (HR)","paramValue":"0.909","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.413","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.089","groupDescription":"Teff-high WT Population","groupIds":["OG000","OG002"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1043","paramType":"Hazard Ratio (HR)","paramValue":"0.671","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.912","ciPctValue":"95","ciUpperLimit":"1.665","groupDescription":"ITT WT","groupIds":["OG001","OG002"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1730","paramType":"Hazard Ratio (HR)","paramValue":"1.232","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.792","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.483","groupDescription":"ITT WT","groupIds":["OG000","OG002"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.6145","paramType":"Hazard Ratio (HR)","paramValue":"1.084","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nMedian is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nMedian is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nMedian is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"155"},{"groupId":"OG002","value":"129"}],"units":"Participants"}],"title":"Dyspnea in Teff-high WT Population"},{"categories":[{"measurements":[{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nMedian is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nMedian is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Value is not available due to an insufficient number of participants with the event.\n\nMedian is not reached and the confidence limit is not estimable by Brookmeyer and Crowley method due to insufficient observed events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"348"},{"groupId":"OG001","value":"356"},{"groupId":"OG002","value":"336"}],"units":"Participants"}],"title":"Dyspnea in ITT-WT Population"}],"denoms":[{"counts":[{"groupId":"OG000","value":"348"},{"groupId":"OG001","value":"356"},{"groupId":"OG002","value":"336"}],"units":"Participants"}],"description":"EORTC QLQ-C30 is a validated \\& reliable self-report measure (Aaronson et al.1993;Fitzsimmons et al.1999) that consists of 30 questions that assess 5 aspects of patient functioning (physical,emotional,role, cognitive,and social), 3 symptom scales (fatigue,nausea \\& vomiting, pain),global health/quality of life,and six single items (dyspnea,insomnia, appetite loss,constipation,diarrhea, and financial difficulties). EORTC QLQ-C30 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life);however a high score for a symptom scale or item represents a high level of symptomatology or problems. A ≥10-point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al.1998).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.","id":"OG000","title":"Arm A (Atezolizumab+Paclitaxel+Carboplatin)"},{"description":"Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.","id":"OG001","title":"Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)"},{"description":"Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.","id":"OG002","title":"Arm C (Bevacizumab+Paclitaxel+Carboplatin)"}],"paramType":"MEDIAN","populationDescription":"Teff-high WT population is defined as the Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. ITT-WT population is defined as the ITT population excluding patients with an activating EGFR mutation or ALK translocation.","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately 29 months","title":"Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms Determined by European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Score","type":"SECONDARY","unitOfMeasure":"Months"}